Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women.

被引：0
|
作者：
Kuritani, J
Abdelhameed, M
Boyeson, M
Dixon, RM
Pfefferkorn, C
Yonezawa, J
Shindo, T
Minami, Y
Buzdar, AU
机构：
[1] Taiho Pharmaceut Co Ltd, Tokyo, Japan
[2] Covance Clin Res Unit Inc, Madison, WI USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456
引用
下载
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [21] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor
    Dennie, Justin
    Vandell, Alexander G.
    Inoue, Satoshi
    Gajee, Roohi
    Pav, Joseph
    Zhang, George
    Zamora, Cynthia
    Masuda, Nobuhisa
    Uchiyama, Minoru
    Yamada, Makiko
    Senaldi, Giorgio
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565
  • [22] A phase I safety, pharmacokinetic, and pharmacodynamic study of ascending single, oral doses of ICA-17043, a novel Gardos channel inhibitor for the treatment of Sickle Cell Disease.
    Rigdon, G
    Stocker, J
    McNaughton-Smith, G
    Hull, H
    Leese, P
    BLOOD, 2000, 96 (11) : 20B - 21B
  • [23] A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers
    Faaij, RA
    Burggraaf, J
    Schoemaker, RC
    van Amsterdam, RGM
    Cohen, AF
    THROMBOSIS AND HAEMOSTASIS, 1999, : 853 - 853
  • [24] Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects
    Kovanda, Laura L.
    Sullivan, Sean M.
    Smith, Larry R.
    Desai, Amit V.
    Bonate, Pete L.
    Hope, William W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (06)
  • [25] A Phase 1, Subject-and Investigator blinded, Sponsor unblinded, Placebo-controlled, Randomized, 2 part, Sequential, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS 1501a in Healthy Young Subjects and Healthy Postmenopausal Women.
    Dishy, Victor
    Kang, Dongwoo
    Warren, Vance
    Maxwell, William
    Levinson, Benjamin
    Kochan, Jarema
    He, Ling
    Baz-Hecht, Merav
    Fukuda, Chie
    Koga, Junichi
    Tsuda, Eisuke
    Watanabe, Ko
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S107 - S108
  • [26] A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
    Hussaini, Azra
    Mukherjee, Rajat
    Berdieva, Dina M.
    Glogowski, Christen
    Mountfield, Richard
    Ho, Peter T. C.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (02): : 337 - 344
  • [27] A Phase I, Double-Blinded, Randomized, Placebo-Controlled Ascending IV Single-Dose Study Assessing the Safety, Tolerance, and Pharmacokinetics of Neu2000 in Healthy Volunteers
    Cho, Jaeyoung
    Cho, Sung I.
    Schroff, Robert
    Abbott, Robert T.
    Noh, Jai S.
    Yoon, Jaeseung
    Gwag, Byoung J.
    STROKE, 2009, 40 (04) : E250 - E250
  • [28] A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF TAS5315-A NOVEL HIGHLY SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE-IN HEALTHY MALE VOLUNTEERS
    Kumagai, Yuji
    Tanaka, Yoshiya
    Murata, Mitsuru
    Takeuchi, Tsutomu
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 750 - 750
  • [29] Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study
    Lee, Dae Young
    Lee, Min Jung
    Ryu, Chaelim
    Lee, Heewon
    Brooks, Ashley
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (01):
  • [30] A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.
    Sayegh, L.
    Rufiange, M.
    Sadoune, A. Ait
    Sicard, E.
    Massicotte, J.
    Lefebvre, M.
    Colin, P.
    Ranger, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S63 - S64
12345